|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS | |||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||
| VAT receivable | |||||||||||||||||||
| Operating lease right-of-use assets, net | |||||||||||||||||||
| Advance to supplier | |||||||||||||||||||
| Cash | |||||||||||||||||||
| Short term loan receivables | |||||||||||||||||||
| Other receivables | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| NON-CURRENT ASSETS | |||||||||||||||||||
| Right-of-use asset, net | |||||||||||||||||||
| Intangible Asset, net | |||||||||||||||||||
| Fixed assets, net | |||||||||||||||||||
| Total non-current assets | |||||||||||||||||||
| TOTAL ASSETS | |||||||||||||||||||
| CURRENT LIABILITIES | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Contract liabilities | |||||||||||||||||||
| Taxes payable | |||||||||||||||||||
| Accrued interest on notes | |||||||||||||||||||
| Notes payable, net of unamortized OID of $0 and $31,250, respectively | |||||||||||||||||||
| Accrued liabilities and other payables | |||||||||||||||||||
| Lease liability | |||||||||||||||||||
| Payable for purchase of 10% equity interest of Zhonghong | |||||||||||||||||||
| Interest payable on entrusted loans | |||||||||||||||||||
| Entrusted loan payable | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| NONCURRENT LIABILITIES | |||||||||||||||||||
| Taxes payable | |||||||||||||||||||
| Lease liability | |||||||||||||||||||
| Total noncurrent liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| STOCKHOLDERS’ EQUITY | |||||||||||||||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized, 22,959,127 and 20,951,878 shares issued and outstanding | |||||||||||||||||||
| Additional paid in capital | |||||||||||||||||||
| Statutory reserve | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||||
Loading...
